ReviewRadiologie (Heidelberg, Germany)2026
[Cardiac side effects of immunotherapy : Role of imaging in immuno-oncology].
Review in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunotherapies have become an integral part of modern oncology. Despite their therapeutic success, they are associated with cardiotoxic side effects that require early detection. Cardiac magnetic resonance imaging (CMR), as a noninvasive modality, enables precise tissue characterization of immune-mediated myocardial injury.
objectivesTo present cardiotoxic effects of immunotherapies and the role of CMR in diagnosis and risk stratification. MATERIALS AND
methodsCurrent scientific literature and clinical guidelines were reviewed regarding the incidence, pathophysiology, and imaging-based diagnosis of cardiotoxic effects related to immunotherapies.
resultsMyocarditis associated with immune checkpoint inhibitors is rare but linked to high mortality. Chimeric antigen receptor (CAR)-T-related cardiotoxicity often occurs in the context of cytokine release syndrome and can be assessed by CMR with respect to both functional and structural myocardial changes.
conclusionCMR plays a central role in the noninvasive diagnosis of immunotherapy-related cardiotoxicity and is essential for clinical decision-making and risk stratification.
Indexed as
Identifiers
41400822What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.